The IV fluid transfer drugs devices market is anticipated to march steadily in the coming years from 2025 to 2035, energizing by the grans of intravenous (IV) drug delivery enhancement in hospitals, clinics, and homecare.
Devices such as IV catheters, transfer spikes, vial adapters, and connectors secure the transfer of fluids and drugs through IV therapy in an accurate, safe, and sterile way. The critical growth drivers include rising hospitalization rates, prevalence of chronic diseases, increased surgical volumes, and the need for rapid drug administration
New advanced devices and materials that are safety-engineered designs and closed systems for drug or fluid transfer avoid contamination, needle-stick injuries, and medication dosing errors. Another trend that expands the market further is the growing tendency toward outpatient care and home infusion therapy or chemotherapy administration.
The global IV fluid transfer drugs devices market is projected to grow at a CAGR of 3.3%, rising from USD 7,163.9 million in 2025 to approximately USD 9,911.8 million by 2035.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 7,163.9 Million |
| Projected Market Size in 2035 | USD 9,911.8 Million |
| CAGR (2025 to 2035) | 3.3% |
North America leads the market primarily owing to an excellent healthcare infrastructure, high inpatient and day surgery bed volumes, and acceptance of new sophisticated drug delivery systems. The USAhas the lion's share in that with safety mandates, increasing chemotherapy procedures, and most closed-system application in preventing handlers from hazardous drug exposure.
More than 90% of hospitalized patients in the United States receive IV therapy according to WHO, and that increases the demand for devices for drug and fluid transfer constantly in all sectors of care.
It is followed closely by Europe, endowed with patient safety laws, hospital modernization programs, and the growing need for preventing infection in intravenous therapy. Germany, France, and the UK lead in adopting innovative transfer technologies and needleless access systems.
The adoption of CSTDs and standard fluid transfer protocols is further driven by the European Medicines Agency (EMA), which promotes safe IV drug handling. According to WHO, Europe keeps shifting gears on reducing hospital-acquired infections through improved usage of IV devices.
Asia-Pacific is the fastest-growing region. Notably, countries investing such as China, India, and Japan are developing systems for safer medication delivery as these countries face the disparity in healthcare quality and accessibility. According to UN statistics, growing incidences of cancer and chronic conditions increasingly exposed to infusion therapy sessions in the Asia-Pacific have caused the stimulation of demand for safe and sterile IV transfer devices.
Device cost, training gaps, and cross-contamination risks
Even though the market is growing, the high initial expense of adopting sophisticated IV drug transfer systems and their limited availability in rural geographies can badly affect access. A well-trained workforce creates this continued feature of aseptic technique and use of the device, which is usually missing in setups that are poorly resourced.
The risk of cross-contamination and dosing errors still exists when conventional systems are used without adequate safety features. WHO states that safe injection and infusion practices are very vital to bringing down the global burden of healthcare-associated infections.
Closed-system devices, home infusion expansion, and oncology applications
The market shifts towards closed-system transfer devices opens new avenues for protecting from hazardous drug exposure with a major focus on oncology and critical care. Devices that enable multi-dose vial access, drug wastage reduction, and needle-free transfer of drugs are witnessing increased acceptance.
Home infusion therapy development is quickly accelerating because of an elderly population and a newer value-based care model. Portable and user-friendly IV fluid transfer systems are being designed to respond to this need. In the view of WHO, home-based care models together with smart infusion solutions would be necessary to fulfill the vision of universal health coverage by 2035.
From 2020 to 2024, the market witnessed robust growth, largely propelled by COVID-induced hospitalizations and fluid resuscitation, medication infusion, and infection control needs. Hospitals began procuring these sterile IV sets, connectors, and vial access devices in larger quantities. Manufacturers hastened disposable system innovation to facilitate safety and scalable operation.
The period from 2025 to 2035 will see the market involve AI-assisted drug verification, RFID tagging of transfer devices, and integration with smart infusion pumps. Sustainability initiatives will demand the adoption of environment-friendly materials for making these devices, with the accompaniment of internationally recognized regulatory rules for the standardization of IV drug transfer practices.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Emergency procurement and basic sterility standards |
| Consumer Trends | Focus on safety and hospital-based IV therapy |
| Industry Adoption | Hospitals and infusion clinics |
| Supply Chain and Sourcing | High-volume procurement of disposable kits |
| Market Competition | Dominated by large medtech and IV system providers |
| Market Growth Drivers | COVID-19 demand, aging population |
| Sustainability and Impact | Increased plastic waste from single-use devices |
| Smart Technology Integration | Manual transfer and barcode-based checks |
| Sensorial Innovation | Basic connectors and tubing materials |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Standardization of CSTDs, eco-labeling, and digital traceability |
| Consumer Trends | Growth in home infusion, oncology support, and self-administered therapies |
| Industry Adoption | Expansion into long-term care, homecare, and ambulatory surgical centers |
| Supply Chain and Sourcing | Regional production hubs and customizable device kits |
| Market Competition | Entry of smart-device innovators and connected infusion platforms |
| Market Growth Drivers | Chronic disease management, homecare expansion, and safe oncology delivery |
| Sustainability and Impact | Biodegradable polymers and recyclable packaging solutions |
| Smart Technology Integration | AI verification, RFID tagging, and cloud-connected infusion tracking |
| Sensorial Innovation | Tactile indicators, self-sealing valves, and ergonomic vial adapters |
The USA IV fluid transfer drugs and devices market is growing at a steady pace largely due to developments in infusion safety, increased hospitalization rates, and the rising demand for home IV therapy. Hospitals and ambulatory care centers have advanced to closed system transfer devices (CSTDs) and needle-free connectors to eliminate contamination risks and promote dosage accuracy.
According to OECD, in the USA safe practices of medication administration are given emphasis, especially in oncology and critical care environments. The FDA and CDC's regulations concerning infection prevention are encouraging the acceptance of newer technologies for IV drug transfer.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 3.4% |
In the UK, the IV fluid transfer drugs devices market is supported by NHS guidelines emphasizing aseptic technique, medication safety, and antimicrobial resistance prevention. Demand is increasing for closed IV transfer systems, especially in oncology and neonatal intensive care units.
According to OECD, the UK healthcare system is investing in training and equipment to reduce catheter-related bloodstream infections and dosage errors. Growth is also driven by rising use of pre-filled syringes and advanced infusion pumps that integrate drug transfer safety features.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 3.0% |
The EU market is expanding steadily, with strong adoption in Germany, France, and the Netherlands, where IV fluid transfer safety is a regulatory priority in hospitals and long-term care settings. According to UN, European medical device regulations (MDR) mandate improved risk management and clinical performance of drug transfer systems.
Healthcare providers are increasingly switching to closed and needle-free systems to reduce occupational exposure and cross-contamination. EU-funded health programs are also supporting digitization and smart infusion technologies with built-in safety controls.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 3.2% |
The IV fluid transfer drug device market in Japan is undergoing growth due to increased emphasis on elderly care, control of hospital infection, and precisely accurate dosing. Japanese hospitals are moving toward small, user-friendly transfer systems equipped with advanced sealing and filtration properties.
As per OECD guidelines, Japan's healthcare infrastructure permits frequent use of intravenous therapy, specifically in oncology and dialysis operations. Domestic manufacturers are therefore innovating on sterile, leak-proof connectors and simple transfer sets to decrease an opportunity for preparation time and human error in high-throughput clinical settings.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 3.1% |
The South Korean market thrives on the state support for safety of the patient, high surgical volumes, and the increased number of the elderly in South Korea. IV transfer devices find frequent use in emergency, surgical, and oncology departments to secure medication delivery and infection prevention.
According to OECD reports, the hospital modernization and digital health projects in Korea will encourage the use of closed-system IV transfer devices. The local manufacturers are developing also reasonably priced and high-precision devices tailored for both acute care and home infusion applications.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 3.3% |
The IV fluid transferring drugs into devices markets will show steady growth because modern healthcare systems are now focused on accurate and efficient intravenous therapy. These devices ensure the direct infusion of fluids and drugs into the bloodstream for prompt treatment delivery and controlled timing.
Majority infusion pumps and hospitals dominate the global market share under product type and end user because of their precision, reliability, and clinical-care definition. By improving patient outcome, reducing medication errors, and managing complicated regimens, these segments advance. Hospital infusion pumps help in positioning responsible intravenous therapy highly along with advanced care in the wake of increasing cases of chronic diseases and their demand for novel medical technologies.
Infusion pumps dominate product use due to accurate fluid administration, programmable features, and adaptability to various clinical scenarios
| Product Type | Market Share (2025) |
|---|---|
| Infusion Pumps | 68.5% |
Among all IV fluid transfer drugs devices, infusion pumps lead in the market because they ensure accurate control over the rate and volume of fluid delivery. With programmable features, they allow treatment plans to be customized to accommodate individual patient-specific needs involved in different medical conditions
. Infusion pumps are widely used, and this versatility is one reason they dominate the field. They pump fluid that may contain anything from medication to nutrients and blood products. Other enhancements include integration to electronic health records and compatibility with various infusion sets, further establishing their role as an invaluable part of the modern healthcare milieu.
Hospitals dominate end user adoption due to comprehensive care capabilities, advanced infrastructure, and the necessity for continuous patient monitoring
| End User | Market Share (2025) |
|---|---|
| Hospitals | 66.2% |
Hospitals account for the largest end-user segment in the IV fluid transfer drugs devices market, mainly due to their ability to provide comprehensive medical care for acute and chronic conditions. Infusion pumps are often used to ensure the patient receives a precise quantity of fluids, an important consideration in the recovery of individual patients and the success of their treatment.
The inclination towards hospitals is further supported by their commitment to the latest technological advancements in medical care, availability of trained healthcare professionals, and strict adherence to safety procedures. Hence, as institutions for the highest order of complex procedures and critical care, hospitals are the main environment for the use of IV fluid transfer devices.
The IV drug transfer device industry is slowly growing in response to the demand for safe, efficacious, and contamination-free drug delivery systems for use in any healthcare setup. These devices include IV fluid transfer sets, vial adapters, needleless connection devices, and closed drug transfer systems(CDTS).
Together they assure the preparation and administration of IV medications while minimizing loss of drug, risk of exposure, and microbial contamination. Growth of the market is further supported by the increasing number of hospital admissions, rising use of oncology drugs, antimicrobial resistance protocols, and need for better aseptic techniques in compounding and infusion practices.
WHO states that reducing medication preparation errors and occupational exposure with intravenous therapy should be prioritized for improving patient safety and protection of healthcare workers around the world.
Market Share Analysis by Key Players & IV Drug Transfer Device Providers
| Company Name | Estimated Market Share (%) |
|---|---|
| Becton, Dickinson and Company (BD) | 14-17% |
| ICU Medical, Inc. | 11-14% |
| Baxter International Inc. | 9-12% |
| B. Braun Melsungen AG | 7-10% |
| CODAN Companies | 6-9% |
| Other Providers | 38-45% |
| Company Name | Key Offerings/Activities |
|---|---|
| Becton, Dickinson and Company (BD) | In 2024, expanded the BD PhaSeal ™ Optima system with enhanced vial adapters for oncology drug reconstitution; in 2025, introduced dual-chamber IV fluid connectors to reduce disconnections in critical care. |
| ICU Medical, Inc. | In 2024, upgraded needle-free valve technology in ChemoClave ™ systems for improved anti-reflux control; in 2025, launched pre-attached closed system IV transfer sets for oncology and anesthesia units. |
| Baxter International Inc. | In 2024, released advanced transfer tubing sets with integrated barcode scanning; in 2025, added tamper-evident connections for improved drug traceability and compounding integrity. |
| B. Braun Melsungen AG | In 2024, introduced Luer -lock IV extension sets with built-in flow restrictors; in 2025, enhanced automatic flushing systems for high-risk drug delivery protocols. |
| CODAN Companies | In 2024, launched sterile IV transfer kits for single-use oncology drug handling; in 2025, developed color-coded spike sets to prevent cross-contamination in multi-patient environments. |
Key Market Insights
Becton, Dickinson and Company (BD) (14-17%)
BD is a global leader in closed system transfer devices (CSTDs) and IV safety technology. ItsPhaSeal™ and SmartSite™ platforms support safe handling and transfer of hazardous drugs, particularly in oncology and ICU settings.
The company’s offerings focus on reducing occupational exposure, maintaining sterility, and ensuring drug integrity throughout the IV medication chain.According to WHO, integrating closed systems into intravenous therapy reduces contamination risks and enhances clinician safety.
ICU Medical, Inc. (11-14%)
ICU Medical provides needle-free IV transfer and infusion systems with patented anti-reflux technology. ItsChemoClave™ and MicroClave™ lines are widely used for cytotoxic drug preparation and administration in hospitals, infusion centers, and ambulatory care.According to UN, eliminating sharps and open-system exposure is a top priority for improving occupational safety in global health environments.
Baxter International Inc. (9-12%)
Baxter offers a range of IV administration and transfer solutions, including fluid transfer tubing, connectors, and digital-enabled medication delivery systems. The company emphasizes data integration, secure connections, and error prevention in high-volume medication compounding and delivery.According to OECD , smart infusion tools that reduce risk and automate tracking contribute to improved health system efficiency and drug accountability.
B. Braun Melsungen AG (7-10%)
B. Braun manufactures innovative IV transfer and safety infusion devices, offering features like Luer-lock connectors, automated flushing, and multi-port configurations. The company’s focus includes pediatric and critical care drug transfer safety.According to WHO, improving device engineering in IV therapy helps reduce central line infections and streamline medication workflows.
CODAN Companies (6-9%)
CODAN develops customized IV drug transfer and infusion solutions for oncology, anesthesia, and intensive care. Its systems include sterile kits, color-coded lines, and one-way valves tailored for multi-patient safety and contamination control.According to World Bank Report, supporting scalable, disposable medical devices in low-resource hospitals improves access to safe drug delivery and reduces procedural error rates.
Other Key Players (38-45% Combined)
Several regional manufacturers and specialty medtech firms contribute to access, innovation, and system compatibility in this space. These include:
The overall market size for the IV fluid transfer drugs devices market was approximately USD 7,163.9 million in 2025.
The IV fluid transfer drugs devices market is expected to reach approximately USD 9,911.8 million by 2035.
The demand for IV fluid transfer drugs devices is rising due to the increasing prevalence of chronic diseases, growing geriatric population, and the need for precise and controlled drug administration.
The top 5 countries driving the development of the IV fluid transfer drugs devices market are the United States, Germany, France, Japan, and the United Kingdom.
Infusion pumps and hospital-based usage are expected to command significant shares over the assessment period.
Explore Therapeutic Device Insights
IV Fluid Transfer Drugs Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
